2022 | News Releases | Mitsubishi Chemical Holdings

May 23, 2022 Business

Bio-based Engineering Plastic DURABIO™ Adopted for the Front Grill of Suzuki S-CROSS
NEW

May 19, 2022 Others

Notice on Change of Trade Name and Partial Amendment to Articles of IncorporationNEW

May 19, 2022 Others

Announcement Regarding Adjustment of Conversion Price for Zero Coupon Convertible Bonds due 2024NEW

May 19, 2022 Personnel

Notice Regarding Executive Personnel ChangesNEW

May 19, 2022 Others

Notice Regarding Distribution of Dividends from SurplusNEW

May 13, 2022 Financial Results

Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 (Under IFRS)

May 13, 2022 Business

FDA approval of RADICAVA ORS® for the treatment of ALS

Apr. 27, 2022 Others

Notice Regarding Disposition of Treasury Shares as Equity Compensation in the Form of Restricted Shares

Apr. 27, 2022 Personnel

Announcement of Organizational Changes and Personnel Changes of Mitsubishi Chemical Holdings Group

Apr. 25, 2022 Business

Mitsubishi Chemical Holdings Group Invests in Myoridge,
a Japanese Startup Offering Innovative Products and Services for the Cell Culture Market

Apr. 25, 2022 Business

Swissmedic has accepted the New Oral Edaravone Formulation for the treatment of ALS

Apr. 19, 2022 Business

European Patent Office Declares the Validity of the Mitsubishi Chemical Holdings Group's Patent for the Production and Sale of High-Quality Biomass-Based Polyester Pellets

Apr. 15, 2022 Others

MCHC Selected as Component for Newly Created ESG Index

Apr. 11, 2022 Business

Marketing Authorization Application of Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine (BK1310/MT-2355)

Apr. 4, 2022 Business

Long-Term Safety Profile from Phase 2b Clinical Trials of Parkinson's Disease Drug Candidate (ND0612) Presents at 2022 American Academy of Neurology Annual Meeting

Apr. 1, 2022 Business

Message for New Employees by Jean-Marc Gilson, CEO of Mitsubishi Chemical Holdings Group

Apr. 1, 2022 Personnel

Announcement of Personnel Changes of Mitsubishi Chemical Holdings Group

Mar. 31, 2022 Others

Notice on Absorption-type Merger of a Wholly-owned Subsidiary (Simplified Merger and Short-form Merger)

Feb. 24, 2022 Business

COVID-19 vaccine, “COVIFENZ® ” (MT-2766) has been approved in Canada

Feb. 24, 2022 Personnel

Organizational Changes and Personnel Changes of Mitsubishi Chemical Holdings Group

Feb. 22, 2022 Business

Diamond Edge Ventures, the Corporate Venture Capital Arm of Mitsubishi Chemical Holdings,
Leads Lingrove’s Series A to Scale Production of its Carbon-Negative Ekoa®, Replacing Wood and Plastics in Furniture, Autos, and Interiors

Feb. 3, 2022 Financial Results

Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2022 (Under IFRS)

Jan. 7, 2022 Personnel

Notice Regarding Changes in Representative Corporate Executive Officers

Jan. 7, 2022 Personnel

Announcement of Personnel Changes

Jan. 4, 2022 Business

New Year Message from President and CEO, Jean-Marc Gilson

Jan. 4, 2022 Personnel

Personnel Changes